Cryoport (CYRX) Projected to Post Quarterly Earnings on Tuesday

Cryoport (NASDAQ:CYRX - Get Free Report) will likely be posting its quarterly earnings results after the market closes on Tuesday, March 4th. Analysts expect Cryoport to post earnings of ($0.33) per share and revenue of $58.71 million for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Cryoport Trading Down 1.4 %

NASDAQ CYRX traded down $0.08 on Friday, reaching $5.57. 322,669 shares of the company were exchanged, compared to its average volume of 261,686. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The business's fifty day moving average price is $7.50 and its 200 day moving average price is $7.70. The stock has a market capitalization of $275.33 million, a P/E ratio of -1.65 and a beta of 1.59. Cryoport has a fifty-two week low of $5.32 and a fifty-two week high of $20.10.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CYRX shares. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a report on Friday, January 17th. Roth Mkm decreased their target price on shares of Cryoport from $18.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, November 8th. Finally, Guggenheim started coverage on shares of Cryoport in a report on Thursday, December 19th. They set a "buy" rating and a $11.00 price target for the company. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.29.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company's stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.10% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.